Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00118053 · ClinicalTrials.gov registry record · Phase 2
Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer
A Phase 2 study, sponsored by University of Medicine and Dentistry of New Jersey.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00118053: Clinical Trial Phase 2 study, sponsored by University of Medicine and Dentistry of New Jersey.
NCT00118053 is a Phase 2 study that was terminated before completion, run by University of Medicine and Dentistry of New Jersey. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00118053, a Phase 2 study, was terminated before completion, sponsored by University of Medicine and Dentistry of New Jersey.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving trastuzumab together with docetaxel and carboplatin may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving trastuzumab together with docetaxel and carboplatin works in treating women with stage II, stage III, or inflammatory breast cancer.
Interventions
- DRUG carboplatin
- DRUG docetaxel
- PROCEDURE conventional surgery
- PROCEDURE radiation therapy
- BIOLOGICAL herceptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2005-04 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Why NCT00118053 stopped before completion
NCT00118053 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00118053 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00118053 about?
NCT00118053 is a clinical study titled "Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer". RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as docetaxel and carboplat...
What is the current status of trial NCT00118053?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2005-04. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00118053?
The interventions under investigation include: carboplatin (DRUG), docetaxel (DRUG), conventional surgery (PROCEDURE), radiation therapy (PROCEDURE), herceptin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00118053?
This trial is sponsored by University of Medicine and Dentistry of New Jersey, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00118053's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia